Brainsway Ltd (BRSYF)
OTHER OTC:BRSYF
Want to see BRSYF full AI Analyst Report?
BRSYF Stock Chart & Stats
$11.54
$0.00(0.00%)
At close: 4:00 PM EST
$11.54
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$3.26 - $13.55
Previous CloseN/A
Volume2.42K
Average Volume (3M)0.00
Market Cap
$648.99M
Enterprise Value$565.39M
Total Cash (Recent Filing)$67.97M
Total Debt (Recent Filing)$6.82M
Price to Earnings (P/E)45.3
Beta0.31
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.08
Shares Outstanding40,033,028
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)5.11
Price to Sales (P/S)6.62
P/FCF Ratio21.25
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue10.00
Enterprise Value/Gross Profit13.26
Enterprise Value/Ebitda89.12
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrendSustained multi-year top-line expansion indicates improving market penetration and adoption of Deep TMS systems. Steady revenue scaling supports recurring consumables and service revenue, improves operating leverage, and provides a broader installed base that can drive durable, repeatable cash generation.
High Gross MarginsConsistently high gross margins create a structural advantage: they enable substantial contribution to fixed costs and R&D, allow scalable operating leverage as revenue grows, and provide a buffer against pricing pressure. High product margins support long-term profitability sustainability.
Improved Cash Generation & Strong Balance SheetMaterial improvement in operating and free cash flow combined with equity growth (about 19.6M in 2020 to 73.2M in 2025) strengthens financial flexibility. Positive cash generation funds reinvestment, reduces reliance on external financing, and supports sustainable growth initiatives over the medium term.
Bears Say
Historical Cash-Flow InconsistencyPrior periods of negative free cash flow indicate the company has not reliably converted profits to cash over time. This legacy inconsistency raises execution risk: if revenue growth or margins weaken, cash generation could deteriorate quickly, constraining investments and increasing financing vulnerability.
Profitability Is RecentThe shift to profitability is encouraging but recent, so operating discipline and margin sustainability remain unproven across a full cycle. A reversion to prior loss patterns or margin compression would quickly reverse gains, making the current profit profile less durable without sustained execution.
Dependence On Reimbursement And AdoptionRevenue and recurring streams depend on clinic utilization, payer reimbursement, and regulatory/clinical adoption. These external, slow-moving factors can limit demand, delay access, and create volatile adoption curves, making long-term growth contingent on sustained regulatory and reimbursement progress.
Brainsway News
BRSYF FAQ
What was Brainsway Ltd’s price range in the past 12 months?
Brainsway Ltd lowest stock price was $3.26 and its highest was $13.55 in the past 12 months.
What is Brainsway Ltd’s market cap?
Brainsway Ltd’s market cap is $648.99M.
When is Brainsway Ltd’s upcoming earnings report date?
Brainsway Ltd’s upcoming earnings report date is May 13, 2026 which is in 23 days.
How were Brainsway Ltd’s earnings last quarter?
Brainsway Ltd released its earnings results on Mar 11, 2026. The company reported $0.084 earnings per share for the quarter, beating the consensus estimate of N/A by $0.084.
Is Brainsway Ltd overvalued?
According to Wall Street analysts Brainsway Ltd’s price is currently Overvalued.
Does Brainsway Ltd pay dividends?
Brainsway Ltd does not currently pay dividends.
What is Brainsway Ltd’s EPS estimate?
Brainsway Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Brainsway Ltd have?
Brainsway Ltd has 40,033,028 shares outstanding.
What happened to Brainsway Ltd’s price movement after its last earnings report?
Brainsway Ltd reported an EPS of $0.084 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Brainsway Ltd?
Currently, no hedge funds are holding shares in BRSYF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Brainsway Ltd
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
BRSYF Company Deck
BRSYF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in revenue and system shipments, successful strategic investments, and improved financial guidance. However, there were increased operating expenses and delays in FDA clearance for a strategic partner's product. Overall, the positives significantly outweigh the negatives.View all BRSYF earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
0.23% Mutual Funds
0.23% Other Institutional Investors
99.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---